Case Studies

Rune created a novel product concept from a potent old three times daily anti-depressant with side effect issues of nausea and vomiting and a difficult, multi-stage manufacturing process.

All issues were dealt with via a modern manufacturing process and novel formulation to allow once daily dosing for a completely new indication.

The product was sold during development and is now achieving in excess of USD 200M annual sales, 3 years post launch.

Rune has created a novel product concept from a potent old once daily anti-psychotic with side effect issues of nausea, vomiting and drowsiness.

All issues have now been dealt with in the 3rd prototype novel product created by Rune – achieving the potential for once weekly oral capsule dosing.

Rune is now in a Series B Fundraise to take this product through regulatory and manufacturing approval prior to worldwide launch.

Rune has created a novel trans-dermal delivery concept for an ADHD treatment which has been taken through PoC.

It is now ready to move through regulatory scale bio-equivalence studies and manufacturing upscaling with stability testing prior to regulatory submission.

Rune is currently working with single-country pharmaceutical companies to help engage regional distributors of products ensuring globalisation of sales and maximization of revenue.